CIK 0001472091
- Non-accelerated filer
- Smaller reporting company
PDS Biotechnology Corp
Sign in to watch- Ticker
- PDSB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 264231384
- Phone
- +1 800-208-3343
- Business address
- 303A COLLEGE ROAD EAST, PRINCETON, NJ, 08540
- Former names
- Edge Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-06-16 | Vaish Renu V.P., Global Reg. Affairs | Exercise or conversion · Stock Option (right To Purchase) | −5,000 | 115,605 | ||
| 2016-03-11 | HEALY JAMES Director | Purchase | +541,343 | $7.30 | $4.0M | 2,852,711 |
| 2016-03-11 | LOUGHLIN JAMES J Director | Purchase | +100 | $7.58 | $758 | 100 |
| 2016-03-11 | LOUGHLIN JAMES J Director | Purchase | +13 | $7.63 | $99 | 113 |
| 2016-03-11 | LOUGHLIN JAMES J Director | Purchase | +500 | $7.64 | $4K | 613 |
| 2016-03-11 | LOUGHLIN JAMES J Director | Purchase | +1,107 | $7.64 | $8K | 1,720 |
| 2016-03-11 | LOUGHLIN JAMES J Director | Purchase | +600 | $7.64 | $5K | 2,320 |
| 2016-03-11 | LOUGHLIN JAMES J Director | Purchase | +500 | $7.63 | $4K | 2,820 |
| 2016-03-11 | LOUGHLIN JAMES J Director | Purchase | +180 | $7.63 | $1K | 3,000 |
| 2016-03-01 | Faleck Herbert J Chief Medical Officer | Grant or award · Stock Option (right To Purchase) | +25,000 | 25,000 | ||
| 2016-02-16 | MARCHIO ALBERT N II Chief Accounting & Ops Officer | Grant or award · Stock Option (Right to Purchase) | +35,000 | 35,000 | ||
| 2016-02-16 | Macdonald R. Loch Chief Scientific Officer | Grant or award · Stock Option (Right to Purchase) | +85,000 | 85,000 | ||
| 2016-02-16 | Vaish Renu V.P., Global Reg. Affairs | Grant or award · Stock Option (Right to Purchase) | +30,500 | 30,500 | ||
| 2016-02-16 | Leuthner Brian A President and CEO | Grant or award · Stock Option (Right to Purchase) | +230,000 | 230,000 | ||
| 2016-02-16 | Einhorn Andrew J. Chief Financial Officer | Grant or award · Stock Option (Right to Purchase) | +50,000 | 50,000 | ||
| 2016-02-16 | Yaman Alpaslan V.P., Technical Ops. & Mfg. | Grant or award · Stock Option (Right to Purchase) | +35,000 | 35,000 | ||
| 2016-02-16 | MIDDLEKAUFF W BRADFORD Senior VP, GC and Secretary | Grant or award · Stock Option (Right to Purchase) | +35,000 | 35,000 | ||
| 2016-02-16 | Faleck Herbert J Chief Medical Officer | Grant or award · Stock Option (Right to Purchase) | +110,000 | 110,000 | ||
| 2015-11-16 | MIDDLEKAUFF W BRADFORD Senior VP, GC and Secretary | Grant or award · Stock Option (Right to Purchase) | +80,000 | 80,000 | ||
| 2015-10-06 | Conti Kurt G Director | Conversion | +160,810 | 160,810 |
Page 14 of 18 · 346 trades